ERITROLAG 250mg price in UAE

Overview

Welcome to Dwaey, specifically on ERITROLAG 250mg Tablets/Enteric-coated page.
This medicine contains an important and useful components, as it consists of Erythromycin (as stearate).
ERITROLAG 250mg is available in the market in concentration 250mg/Tablet and in the form of Tablets/Enteric-coated.

LAGAP SA is the producer of ERITROLAG 250mg and it is imported from UAE, The most popular alternatives of ERITROLAG 250mg are listed downward .

Mode Of Action

Erythromycin inhibits protein synthesis by irreversibly binding to the 50S ribosomal subunit thus blocking the transpeptidation or translocation reactions of susceptible organisms resulting in stunted cell growth.

Indication

Susceptible infections
Respiratory tract infections
Enteritis
Pertussis
Trench fever
Chanroid
Chlamydial infections
Diphtheria
Legionnaire's disease
Pneumonia
Sinusitis
Bronchitis
Acne
Rheumatic fever
Neonatal conjunctivitis.

Precaution

Increased risk of cholestatic hepatitis when treatment is >10 days or in patients with previous history of erythromycin usage. History of hepatic disorders; arrhythmias; prolonged QT interval; lactation. Monitor liver function. Avoid estolate in liver impairment. Caution when using lactobionate in patients with severe renal impairment. May aggravate muscle weakness in patients with myasthenia gravis. Lactation: distributed in breast milk, use with caution; AAP categorizes as compatible with breastfeeding

Side Effects

1-10% Abdominal pain (8%)
Headache (8%)
Nausea (8%)
Diarrhea (7%)
Rash (3%)
Vomiting (3%)
Dyspepsia (2%)
Flatulence (2%)
Pain (2%)
Pruritus (1%)
Pseudomembranous colitis Hypertrophic pyloric stenosis
Anaphylaxis
Fever
Mild allergic reactions
Urticaria
Skin eruptions
Tinnitus <1% Cholestatic hepatitis
Confusion
Hallucinations
Hearing loss
Hypotension
Nervous system effects including seizures
Torsade de pointes
Ventricular tachycardia
Vertigo Potentially Fatal: Hepatotoxicity
cholestatic jaundice; raised serum transaminases; eosinophilia.

Contra indication

Hypersensitivity; porphyria; hepatic impairment; pregnancy.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.